Tumour cells engineered to secrete interleukin-15 augment anti-tumour immune responses in vivo by Hazama, S et al.
Interleukin (IL)-15 is a novel cytokine that uses b- and g-chains of
the IL-2 receptor (R) for signal transduction and shares biologic
activities with IL-2 (Giri et al, 1994; Grabstein et al, 1994). IL-15
has been reported to activate and stimulate the proliferation of
T- and B-lymphocytes (Armitage et al, 1995; Mori et al, 1996). It
also stimulates the proliferation of natural killer (NK) cells
(Carson et al, 1996) and facilitates the induction of cytolytic
effector cells including cytotoxic T-lymphocyte (CTL) and
lymphokine-activated killer (LAK) cells (Gamero et al, 1995;
Lewko et al, 1995; Munger et al, 1995). These properties suggest
that IL-15, like IL-2, may be of value in cancer treatment. Unlike
IL-2, however, IL-15 is produced by a wide variety of tissues and
cells that include activated monocytes/macrophages, skeletal
muscle, kidney, epithelial cells, activated endothelial cells and
placenta (Grabstein et al, 1994; Bamford et al, 1996). Moreover,
the IL-15R employs a unique a-chain which has a higher affinity
and broader tissue distribution than the IL-2R a-chain (Andeson
et al, 1995; Giri et al, 1995). These differences in the expression
pattern of IL-15 and its receptor compared to the IL-2/IL-2R
system suggest unique in vivo roles for IL-15.
Transfection of various cytokine genes [IL-2, IL-4, IL-6, IL-7,
IL-8, IL-10, IL-12, IL-13, tumour necrosis factor (TNF)-a, inter-
feron (IFN)-g, granulocyte-macrophage colony stimulating factor
(GM-CSF), granulocyte-colony stimulating factor (G-CSF) and
macrophage inflammatory protein (MIP)-1a (Colombo and Forni,
1994; Hirose et al, 1995; Lebel-Binay, et al, 1995; Zitvogel et al,
1995)] into tumour cells results in inhibition of tumour growth.
This effect is mediated through the infiltration of T-lymphocytes,
macrophages and/or polymorphonuclear leucocytes into the
tumour sites. These studies have shown the primary effects of
cytokine release as well as effects seen with the induction of
secondary cytokines (Colombo and Forni, 1994). However, there
are no studies that have examined transfection of the IL-15 gene
into animal tumour cells, and its effects on the anti-tumour
immune response in vivo.
In this study we transfected tumour cells with an IL-15 expres-
sion vector and examined the response to the IL-15-secreting
tumour cells in both BALB/c and BALB/c nu/nu mice with defec-
tive T-lymphocyte-mediated immunity.
MATERIALS AND METHODS
RT-PCR and primers
RNA isolation and reverse transcription polymerase chain reaction
(RT-PCR) were carried out as previously described with some
modifications (Iizuka et al, 1995). Briefly, cells (5 ´ 106) were
solubilized in 1 mL of TRIzol reagent (Life Technologies, Grand
Island, NY, USA) and total cellular RNA was isolated according
to the manufacturer’s instructions. One microlitre of total RNA
(1 mg) was added to 19 ml of RT-mixture (Takara, Ohtsu, Japan).
After mixing, the samples were incubated at 30°C for 10 min,
55°C for 30 min, 95°C for 5 min and 4°C for at least 5 min. PCR-
mixture (80 ml) (Takara) containing 100 nM primers was added to
the RT products. PCR cycling parameters were as follows for the
isolation of human IL-15 (hIl-15) cDNA and for the selection of
hIL-15 mRNA-expressing clones: denaturation at 94°C for 1 min,
annealing at 60°C for 1 min, and extension at 72°C for 2 min. PCR
amplification of the IL-15 and b-actin genes utilized 40 and 28
cycles respectively.
The primer sequences were as follows – IL-15-5¢ primer:
5¢-GATCCCAAGCTTCCGTGGCTTTGAGTAATGAG-3¢ and 3¢
primer: 5¢-CGCGCCTCTAGAGCAATCAAGAAGTGTTGATG-3¢
(Grabstein et al, 1994); b-actin-5¢ primer: 5¢-ATGGATGAT-
GATATCGCCGCGCT-3¢ and 3¢ primer: 5¢-CGGACTCGTCAT-
ACTCCTGCTTG-3¢ (Tokunaga et al, 1986). The expected sizes of
the PCR products were 532 bp for IL-15 and 1224 bp for b-actin.
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To determine whether Meth-A cells used produce murine IL-15,
other primers for human and murine IL-15 were prepared using the
sequences without homology between human and murine IL-15
mRNA. PCR cycling parameters were the same as described above.
PCR amplification of human and murine IL-15 was 28 cycles, and
b-actin was 24 cycles. The primer sequences were as follows –
human IL-15-5¢ primer: 5¢-GCCAACTGGGTGAATGTAATA-3¢
and 3¢ primer: 5¢-TCAAGAAGTGTTGATGAACAT-3¢; murine IL-
15-5¢ primer: 5¢-GAGGAATACATCCATCTCGTGC-3¢ and 3¢
primer: 5¢-GAGTCATGTTACTGTACTCATG-3¢ (Nishimura et al,
1998); b-actin-5¢ primer: 5¢-TCGACAACGGCTCCGGCATGT-3¢
and 3¢ primer: 5¢-GCTGATCCACATCTGCTGGAA-3¢.
The expected sizes of the PCR products were 347, 296 and
1046 bp for human-IL-15, murine IL-15 and b-actin respectively.
The PCR products were subjected to 1% agarose gel
electrophoresis and visualized by staining with ethidium bromide.
Human IL-15 cDNA expression vector
A human IL-15 cDNA was isolated by RT-PCR using total RNA
purified from lipopolysaccharide-stimulated human peripheral
blood mononuclear cells. The PCR fragment was cloned into a
HindIII/XbaI site of the pGEM-4Z plasmid (Promega, Madison,
WI, USA), and the nucleotide sequence was confirmed by
sequence analysis. The same fragment was then recloned into a
HindIII/XbaI site of the pRc/CMV eukaryotic expression vector
(Invitrogen, San Diego, CA, USA).
Tumour cells and transfection
The Meth-A cell line, a methylcholanthrene-induced fibrosarcoma
of BALB/c origin (DeLeo et al, 1977), was maintained in RPMI-
1640 medium supplemented with 10% heat-inactivated fetal calf
serum, 100 U ml–1 penicillin G and 100 g ml–1 streptomycin.
Subconfluent cultures in 100-mm petri dishes were transfected with
5 mg of hIL-15 expression plasmid or vector alone using the
lipofectAMINE reagent (Life Technologies) according to the manu-
facturer’s instructions. G418 (200 mg ml–1) (Life Technologies) was
added to the cells 48 h later. G418-resistant clones were isolated and
expanded in culture medium containing 100 mg ml–1 of G418.
Measurement of IL-15 production by bioassay
Each transfectant as well as the parental Meth-A cells (1 ´ 106
cells ml–1) were cultured in serum-free RPMI-1640 without G418
for 24 h. The culture supernatants were collected by centrifugation
for 5 min at 400 g and were concentrated using Centricon concen-
trators (10 000) (Grace, Danvers, MA, USA) to tenfold enrichment
prior to bioassay. IL-15-dependent CTLL-2 cells (4000 cells per
well) in 96-well flat microtitre plates were incubated with culture
medium supplemented with 5 ´ 10–5 M 2-mercaptoethanol in
the presence of various concentrations of hIL-15 (Genzyme,
Cambridge, MA, USA) or culture supernatant with or without
anti-hIL-15 monoclonal antibody (mAb; M111, Genzyme) at
various concentrations. After a 20 h incubation
50 mg of (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide) (MTT) (Chemikon International, Temecula, CA, USA)
were added to each well, and the reaction was allowed to incubate
for an additional 4 h at 37°C. Isopropanol with 0.04 N hydro-
chloric acid (100 ml) was then added. Colour development at a
wavelength of 540 nm was monitored by an enzyme-linked
immunorsorbent assay (ELISA) reader (SLT Labinstruments,
Austria). The sensitivity of this bioassay was 50 pg ml–1.
Measurement of IL-15 production by ELISA
IL-15 levels were measured using ELISA (BioSource, Camarillo,
CA, USA). In each assay a standard curve using recombinant
cytokine was constructed and each sample assayed in duplicate.
The sensitivity of the assay was 37 pg ml–1.
Animal studies
Seven-week-old female BALB/c mice and male BALB/c nu/nu
mice were purchased from Japan SCL (Hamamatsu, Japan).
Injections of Meth-A cells were carried out with freshly prepared
suspensions at a concentration of 2 ´ 107 cells ml–1. The total
number of tumour cells injected per animal was 2 ´ 106. All injec-
tions were subcutaneous (s.c.) in the right lower abdominal quad-
rant via a 27-gauge needle. Tumour volumes were measured in
mm3 with a vernier caliper and determined according to the
following formula: a ´ b2 ¸ 2, where a is the larger and b the
smaller of the two dimensions. All animal experiments were
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Figure 1 Expression of IL-15 and b-actin in G418 resistant clones and parental Meth-A cells (lane p). Lane a is the 1 kb DNA ladder. Lanes 1–18 represent
IL-15-transfected clones and lanes 19–24 vector-only clones. IL-15 mRNA was detected in clones 2, 14 and 16. Arrows indicate IL-15 and b-actin mRNA
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Figure 2 Expression of human IL-15, murine IL-15 and murine b-actin in
clones 2, 14, 16 and 20. SM is the 1 kb DNA ladder. Clones 2, 14 and 16
represent human IL-15 transfectants, and clone 20 vector-only transfectant.
Human IL-15 mRNA was detected in clones 2, 14 and 16, whereas murine
IL-15 was not detected in any transfectant. Arrows indicate IL-15 and b-actin
mRNA. SM, size marker; mMo |, lipopolysaccharide-stimulated murine
macrophages; bp, base pair1422 S Hazama et al
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conducted in accordance with UKCCCR Guidelines on Animal
Welfare (Workman et al, 1988).
Rechallenge with Meth-A or colon 26
Thirty days after disappearance of the initial Meth-A/IL-15
implantation, 20 mice were injected with 2 ´ 106 parental Meth-A
cells in the previously uninjected side (left) of the lower abdominal
quadrant. Colon-26 cells, a murine colon adenocarcinoma derived
from BALB/c mice (Corbett et al, 1975), were also injected into
both non-immunized and immunized mice (BALB/c mice that had
rejected Meth-A/IL-15 cells).
Antibody treatment in vivo
In vivo neutralization of produced hIL-15 in tumorigenesis studies
was accomplished by intraperitoneal injection with a mouse anti-
h IL-15 mAb (M111, Genzyme) at 50 mg per 0.2 ml per injection
on days 0 (the day of tumour cell injection), 3, 7, 10, 14 and 17
after tumour cell injection. This antibody at approximately
5–10 mg ml–1 neutralized approximately 80% of bioactivity
induced by 5 ng ml–1 IL-15 in CTLL-2 cells. Normal mouse IgG
(50 mg per 0.2 ml per injection; Caltag Laboratories, Burlingame,
CA, USA) was injected into untreated mice on the same schedule.
Histologic evaluation and immunohistochemical
staining
On day 7 and 14 after inoculation, the tumours were dissected,
fixed in 10% neutral-buffered formalin and embedded in paraffin.
Sections (4-mm) were stained with haematoxylin and eosin. For
immunohistochemical staining, tissues were embedded in OCT
compound (Ames Division, Miles Laboratories, Elkart, IN, USA),
snap-frozen in liquid nitrogen, and stored at –80°C. Aceton-fixed
6-mm cryostat sections were blocked with goat serum and then
immunostained with optimal dilution of the following rat mAbs:
L3/T4 (CD4: Becton Dickinson, Franklin Lakes, NJ, USA), KT15
(CD8:Serotec, Sapporo, Japan), Mac-1 (CD11b: Caltag). The
slides were then sequentially incubated with biotinated goat anti-
mouse Igs (ZYMED Laboratories, San Francisco, CA, USA) and
ABComplex (DAKO, Tokyo, Japan). Each incubation step lasted
at least 30 min and was followed by a 10 min phosphate-buffered
saline (PBS) wash. Sections were then incubated with 0.03%
hydrogen peroxide and 0.06% 3,3¢diaminobenzidine for 2–5 min,
washed in tap water and counterstained in haematoxylin.
Statistical analysis
Statistical analysis used the Student’s t-test. A value of P < 0.05
was considered statistically significant. Results are presented as
mean ± s.e.m.
RESULTS
Expression of IL-15 in transfectants
Eighteen independent G-418-resistant colonies were isolated and
expanded. RNA was isolated and RT-PCR performed. Three
(2, 14, 16) of 18 clones expressing IL-15 mRNA were selected for
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Figure 3 In vivo growth of Meth-A/IL-15 and Meth-A/Neo cells. BALB/c mice (A) and BALB/c nu/nu mice (B) were implanted subcutaneously with 2 ´ 106 cells
(n = 10). Tumour growth was suppressed in Meth-A/IL-15 (* P < 0.02). Tumour volumes are mean ± s.e.m. (C) In-vivo growth of three IL-15-producing clones
(n = 5). There was no difference in the growth of clones 2, 14 and 16. These clones produced different amount of bioactive IL-15. Tumour volumes are mean.
Each s.e.m. was < 10%. (D) The effect of anti-human IL-15 mAb on the growth of Meth-A/IL-15 in vivo. Mice were treated by intraperitoneal injection with anti-
human IL-15 mAb at 50 mg per injection on days 0, 3, 7, 10, 14, 17, after tumour cell implantation (n = 5). Normal mouse IgG was injected into untreated mice
on the same schedule (n = 5). Arrows indicate the days of antibody injection. The growth of Meth-A/IL-15 was augmented by the injection of anti-human IL-15
mAb. Tumour volumes are mean. Each s.e.m. was < 10%IL-15 gene transfer reduces tumorigenicity in vivo 1423
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bioassay. Endogenous IL-15 mRNA was not detected in Meth-A
cells transfected with vector alone and parental cells (Figure 1).
Endogenous murine IL-15 mRNA was not detected in Meth-A
cells transfected with IL-15 and vector alone (Figure 2). The
production of IL-15 was confirmed by the bioassay of CTLL-2
proliferation. The level of IL-15 production in the transfectants
(106 cells 24 h–1) was 35 pg, 53 pg, and 42 pg for clones 2, 14 and
16 respectively. The bioactivity of each culture supernatant was
neutralized completely by anti-IL-15 antibody at a concentration
of 10 mg ml–1. The Meth-A cells transfected with vector alone
(clones 19–22) and parental cells did not produce bioactive IL-15.
IL-15 levels, measured by the parallel use of an ELISA kit, were
25 pg, 31 pg and 29 pg for clone 2, 14 and 16 respectively.
Moreover, the production of IL-15 by these three clones was stable
for more than 1 year, because the fluctuations of this production
at different times were < 15% in each clone. IL-15 production
could not be detected in the supernatant of the parental cells or
in transfectants by vector alone. We selected clones 16 (named
Meth-A/IL-15), 2 (Meth-A/2), 14 (Meth-A/14) and 20 (Meth-
A/Neo) for further examination.
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Figure 4 Histological examination of tumour implantation sites. BALB/c mice (A–D) were implanted subcutaneously with IL-15-producing Meth-A cells (A, C)
or Meth-A/Neo cells (B, D), and the injection sites were resected 7 (A, B) and 14 days (C, D) after implantation. BALB/c nu/nu mice (E, F) were implanted
subcutaneously with IL-15 producing Meth-A cells (E) or Meth-A/Neo cells (F) and the injection sites were resected 14 days after implantation (haematoxylin
and eosin, ´ 400)1424 S Hazama et al
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Inhibition of tumour growth in vivo
The transfection of IL-15 or vector alone did not alter the growth
properties of Meth-A cells in vitro as analysed by doubling time or
morphology (data not shown). Tumorigenicity of Meth-A/IL-15 and
Meth-A/Neo cells was examined by s.c. injection into BALB/c and
BALB/c nu/nu mice in three independent experiments. In BALB/c
mice Meth-A/IL-15 cells initially grew, then gradually regressed and
were completely rejected within 21 days (n = 10), while Meth-
A/Neo cells grew progressively until they caused the death of the
animals (n = 10) (Figure 3A). There was no difference in the growth
patterns of the three IL-15-secreting clones (n = 5), Meth-A/IL-15,
Meth-A/2 and Meth-A/14, of which production of IL-15 was 42 pg
(106 cells 24 h–1), 35 pg and 53 pg respectively (Figure 3C).
Moreover, the growth of Meth-A/IL-15 (n = 5) was augmented by
the injection of anti-hIL-15 mAb (Figure 3D). In nude mice, both
Meth-A/IL-15 cells (n = 10) and Meth-A/Neo cells (n = 10) grew
progressively and were not rejected, although tumour growth was
relatively inhibited in the case of Meth-A/IL-15 cells (Figure 3B).
Histology at the site of tumour cell injection
Histological analysis of the injected site was performed at 7 and 14
days following the injection of tumour cells in order to charac-
terize the host cellular responses augmented by IL-15 production.
In BALB/c mice, massive infiltration of mononuclear cells and
polymorphonuclear neutrophils was noted on day 7 after the
implantation of Meth-A/IL-15 cells (Figure 4A). Moreover, on day
14, Meth-A/IL-15 cells were scattered and infiltrating cells were
increased (Figure 4C). In contrast, in the case of Meth-A/Neo
cells, few mononuclear infiltrates were observed (Figure 4B, D).
In BALB/c nude mice, few mononuclear cells and neutrophils
were observed at the injection sites of both Meth-A/IL-15 cells and
Meth-A/Neo cells (Figure 4E, F).
Immunohistochemical analysis of tumour implantation sites in
BALB/c mice 7 days after s.c. injection of Meth-A/IL-15 cells
revealed a infiltrate of CD4+ T cell (Figure 5A) and CD11b+ cell
(not shown) in the Meth-A/IL-15 tumour. CD8+ T-cells (Figure
5B) were virtually absent.
Rechallenging with parental Meth-A and colon-26 cells
We next examined whether the primary rejection of IL-15 transfec-
tants leads to protective immunity. Thirty days after disappearance
of the initial Meth-A/IL-15 implantation, 20 mice were injected
with 2 ´ 106 parental Meth-A cells in the previously uninjected
side (left) of the lower abdominal quadrant. In all mice, tumours
were rejected by 21 days, though transient tumour growth was
observed up to the 3rd day after injection (Figure 6A).
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Figure 5 Immunohistochemical analysis of tumour implantation sites in BALB/c mice 7 days after subcutaneous injection of Meth-A/IL-15 cells (A, B) and
rechallenged parental cells (C, D). Staining with the L3/T4 (CD4) (A), KT15 (CD8) (B) revealed an infiltrate of CD4+ T-cell in the Meth-A/IL-15 tumour. CD8+ T-
cells were virtually absent. In the rechallenged sites, there was a predominant infiltration of CD8+ T-cells (D). CD4+ T-cells (C) were virtually absent. Arrows
indicate the positively stained cellsIL-15 gene transfer reduces tumorigenicity in vivo 1425
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Interestingly, the remarkable infiltration of mononuclear cells
without neutrophils at the tumour site was seen 7 days after
implantation (Figure 6B).
Immunohistochemical analysis of rechallenged sites 7 days
after s.c. injection of parental Meth-A cells revealed an infiltrate of
CD8+ T-cells (Figure 5D) and CD11b+ cells (not shown) in the
Meth-A/IL-15 tumour. CD4+ T-cells (Figure 5C) were virtually
absent.
To demonstrate the specificity of the protective immunity
described above, Colon-26 cells, a murine colon adenocarcinoma
derived from BALB/c mice, were injected into both non-
immunized (n = 10) and immunized mice (n = 10). There was no
significant difference in the growth of implanted Colon-26 cells
between non-immunized mice and immunized mice (Figure 7).
DISCUSSION
It is well established that transfected tumour cells, which secrete a
broad variety of cytokines, are rejected due to the cytokine-
induced increase in the host’s anti-tumour defense (Colombo and
Forni, 1994). These effects provide new experimental approaches
for cancer immunotherapy. Namely, tumour cell-targeted cytokine
gene therapy is achieved by the transfer and expression of appro-
priate genes in tumour cells in vitro followed by analysis of their
growth characteristics in vivo. Here we report that such tumour
rejection can be obtained by local IL-15 production.
Different mechanisms have been demonstrated in cells trans-
fected with different cytokines. IFN-g, IL-2, IL-6 and IL-12 trans-
fectants have induced mainly specific CTL activity (Colombo and
Forni, 1994; Zitvogel et al, 1995), while TNF-a, IL-4, MIP-1a and
IL-8 induced non-specific anti-tumour activity and granulocyte
infiltration (Colombo and Forni, 1994; Hirose et al, 1995). A new
cytokine, IL-15, has shown many functional similarities to IL-2,
such as stimulating proliferation of T- and B-lymphocytes and NK
cells (Grabstein et al, 1994; Armitage et al, 1995; Munger et al,
1995; Mori et al, 1996). These properties suggest that IL-15, like
IL-2, may have a role in cancer treatment. However, differences in
the expression pattern of IL-15 and its receptor compared to the
IL-2/IL-2R system also suggest unique in vivo roles for IL-15
(Andeson et al, 1995; Giri et al, 1995; Bamford et al, 1996). The
present study is the first demonstration of the modification of host
immune responses due to the implantation of syngeneic tumour
cells engineered to secrete IL-15.
This study provides two new observations. First, we demon-
strated that hIL-15-transfected tumour cells were rejected
completely in syngeneic mice, but not in nude mice. This rejection
was accompanied by predominantly a mononuclear (CD4+ T-
lymphocyte) and neutrophilic infiltration. It is possible that hIL-15
expressed by the tumour cells may be recognized as foreign
and function as a tumour-rejection antigen for murine T-cells.
However, we observed that the growth of Meth-A/IL-15 was
augmented by anti-IL-15 injection. This result may support the
direct effects of IL-15 on T-lymphocytes. Second, rechallenged
parental cells were also rejected completely. This was associated
with a predominantly mononuclear cell (CD8+ T-lymphocyte)
infiltration, but not a neutrophilic infiltration.
In spite of these demonstrated anti-tumour effects of IL-15 in
vivo, our understanding of the underlying mechanism is rudimen-
tary. IL-15 has been reported to activate and stimulate proliferation
of T- and B-lymphocytes in vitro (Grabstein et al, 1994; Armitage
et al, 1995; Mori et al, 1996). It stimulates the proliferation of NK-
cells and acts as a co-stimulator with IL-12 to facilitate the
synthesis of IFN-g and TNF-a (Carson et al, 1996). IL-15 also
facilitates the induction of cytolytic effecter cells, including CTL
and LAK cells (Grabstein et al, 1994; Gamero et al, 1995; Lewko
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Figure 6 In vivo growth of rechallenged parental Meth-A cells and histology
of the rechallenged sites. (A) After disappearance of the initial Meth-A/IL-15
implantation, 2 ´ 106 parental Meth-A cells were injected into the opposite
(left) lower abdominal quadrant. Tumour volumes are mean ± s.e.m. (B)
Seven days after implantation the injection sites were resected, and paraffin
sections were stained with haematoxylin and eosin (´ 400)
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Figure 7 In-vivo growth of initial-challenged or rechallenged parental
Colon-26 cells. After disappearance of the initial Meth-A/IL-15 implantation,
5 ´ 105 Colon-26 cells were injected into the opposite (left) lower abdominal
quadrant (n = 10). At the same time, Colon-26 cells were injected into non-
immunized mice (n = 10). Tumour volumes are mean. Each s.e.m. was
< 10%*1426 S Hazama et al
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et al, 1995; Munger et al, 1995). In general, it is well-established
that tumour rejection induced by local secretion of cytokines is
mediated by a dual mechanism involving specific and non-specific
anti-tumour effectors. With regard to the specific effects, our
results indicate that IL-15 stimulates in vivo the sensitization of
memory T-lymphocytes which are responsible for the specific
long-lasting anti-tumour protection. Specifically, BALB/c mice
that rejected Meth-A/IL-15 cells were protected against parental
Meth-A tumours associated with CD8+ T-lymphocytic infiltration,
but not against Colon-26 tumours. Direct effects of IL-15 on
T-lymphocytes seems likely since the IL-15 stimulation of T-
lymphocytes may directly utilize the trimolecular IL-15 receptor
complex (Giri et al, 1994, 1995; Grabstein et al, 1994; Andeson
et al, 1995). Interestingly, massive neutrophilic infiltration was
observed in tumour sites of BALB/c mice that rejected Meth-A/IL-
15 cells, though it has been reported that IL-15 does not attract
neutrophils (Wilkinson et al, 1995). These reports suggest that the
neutrophilic infiltration may be due to a cascade of cytokines and
soluble mediators, which were produced by activated T lympho-
cytes and other cells induced by the IL-15 secretion. Cavallo et al
(1992) have reported that rejection of IL-2-transfected tumours is
associated with neutrophil infiltration, and this neutrophil-
dominated rejection generates a long-lasting, tumour-specific, T-
lymphocyte-mediated immune memory. The role of neutrophils
remains to be characterized in our studies.
The amounts of IL-15 secreted may be important. Meazza et al
(1997) showed the poor efficiency of IL-15 natural signal peptides.
They described that substitution of the sequence encoding natural
signal peptide(s) with the one from IgVk chain in the IL-15 cDNA
resulted in a significantly higher secretion of biologically active
IL-15 (15- to 30-fold) upon cDNA transfection. Although the
amount of IL-15 produced by our transduced cells was relatively
low, the in vitro effects were obtained.
In conclusion, these studies demonstrate that IL-15-transfected
cancer cells can elicit an anti-tumour immune response and
suggest that IL-15 may have a role as a component of tumour
vaccines. Further studies are needed to understand the role of
lymphocytes and neutrophils in the response to IL-15.
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